- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07372079
초기 삼중 음성 유방암의 신보조 요법: 화학요법과 병용한 이파롬리맙 및 투본랄리맙 주사제를 이용한 반응 지도적 접근법
조기 삼중음성 유방암에 대한 수술 전 보조 요법: 화학요법과 병용한 이파롬리맙 및 투본랄리맙 주사제를 이용한 반응 지도적 접근
Iparomlimab and Tuvonralimab Injection (QL1706) is a bifunctional combination antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4). This is a prospective clinical study that plans to enroll screened, eligible early-stage breast-cancer patients to receive neoadjuvant QL1706 plus chemotherapy (four cycles of TP ± four cycles of AC). After the four TP cycles, imaging and core biopsy will be performed. Patients who achieve radiologic complete response will proceed directly to surgery; those who do not will receive four additional AC cycles before surgery. A key feature is the incorporation of an response-guided neoadjuvant therapy(RGN)model to identify sensitive patients who can forgo anthracyclines, thereby reducing long-term cardiotoxicity.
연구 개요
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Yongsheng Jia, Doctor
- 전화번호: +86 18622199359
- 이메일: yongshengjia@tjmuch.com
연구 연락처 백업
- 이름: Wenxiao Liu
- 전화번호: +86 18515456035
- 이메일: liuwenxiao2016@outlook.com
연구 장소
-
-
-
Tianjin, 중국
- 모병
- Tianjin Medical University Cancer Institute & Hospital
-
연락하다:
- Yongsheng Jia, Doctor
- 전화번호: +86 18622199359
- 이메일: yongshengjia@tjmuch.com
-
연락하다:
- Jun Zhang, doctor
- 이메일: doctorjunzhang@163.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Voluntarily join this study, sign the informed consent form, and demonstrate good compliance;
- Age: 18-75 years old (at the time of signing the informed consent form);
- ECOG PS score: 0-1; expected survival time exceeding 6 months;
- Patients with primary breast cancer confirmed by histopathological or cytological examination;
- Primary tumor diameter > 2 cm as measured by local standard assessment methods;
- Judged by the investigator to meet the American Joint Committee on Cancer (AJCC) 8th edition breast cancer TNM staging criteria as cT2-cT4, cN0-cN3, cM0, with locally advanced or early-stage, unilateral, and histologically confirmed invasive breast cancer;
- According to the latest ASCO/CAP guideline definitions, histopathologically confirmed early-stage triple-negative invasive breast carcinoma meeting all of the following criteria:Tumors are triple-negative on pathological subtyping, defined as: ER-negative: IHC ≤10%; PR-negative: IHC ≤10%; HER2-negative: IHC 0/1+, or IHC 2+ with negative ISH.
- At least one measurable lesion according to RECIST 1.1;
- The patient agrees to undergo breast cancer resection surgery when meeting the surgical criteria after neoadjuvant therapy;
- PD-L1 expression status is known;
- Major organ functions are in good condition;
- Female subjects of childbearing potential must have a negative serum pregnancy test within 3 days prior to the first dose. If a female subject of childbearing potential engages in sexual activity with a non-sterilized male partner, the subject must use acceptable and effective contraception from screening onward and agree to continue these precautions until 12 months after the last dose of the study drug; periodic abstinence and rhythm methods are not acceptable contraceptive methods.
- The subject is willing to provide core needle biopsy tissue samples for research analysis.
Exclusion Criteria:
- Patients with stage IV metastatic breast cancer or other patients deemed by the investigator as unable to achieve curative surgical resection through neoadjuvant therapy;
- Patients with inflammatory breast cancer;
- Patients who have had or currently have other malignancies within the past 3 years. The following two conditions may be eligible: other malignancies treated with a single surgical procedure, achieving continuous 5-year disease-free survival (DFS); cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the basement membrane)];
- Breast cancer patients who have received antitumor therapies such as chemotherapy, endocrine therapy, or immune checkpoint inhibitors within the past 3 years, or who have undergone breast surgery (except diagnostic biopsy for primary breast cancer);
- Patients who have undergone major surgical treatment, incisional biopsy, or significant traumatic injury within 28 days prior to the start of study treatment (except diagnostic biopsy for primary breast cancer);
- Presence of any active autoimmune disease or a history of autoimmune disease;
- Patients currently using immunosuppressants or systemic hormonal therapy for immunosuppressive purposes (at a dose >10 mg/day prednisone or equivalent steroids) and continuing such treatment within 2 weeks prior to enrollment;
- Allergy to any study drug or any component or excipient of the drug;
- Patients with concomitant diseases judged by the investigator as seriously endangering the subject's safety or affecting study completion, or those deemed unsuitable for enrollment for other reasons.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: QL1706 Combination Therapy
neoadjuvant QL1706 plus chemotherapy (four cycles of TP ± four cycles of AC). |
Participants receive QL1706 every 3 weeks (Q3W) + Albumin-bound paclitaxel every 3 weeks (Q3W) + Cisplatin (Q3W) x 4 cycles. After the four TP cycles, imaging and core biopsy will be performed. Patients who achieve radiologic complete response will proceed directly to surgery; those who do not will receive QL1706 Q3W + epirubicin Q3W + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy before surgery. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
tpCR(ypT0/is ypN0)
기간: 최대 약 27-30주
|
최대 약 27-30주
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
영상학적 완전 관해율 (iCR)
기간: 약 27~30주까지
|
약 27~30주까지
|
|
에피루비신-사이클로포스파마이드 요법 활용률
기간: 최대 약 16주
|
최대 약 16주
|
|
연구자 평가 무사건 생존율 (EFS)
기간: 최대 약 8년
|
최대 약 8년
|
|
부작용(AE)을 경험한 참가자의 비율
기간: 최대 약 60주
|
최대 약 60주
|
|
전체 생존율 (OS)
기간: 최대 약 8년
|
최대 약 8년
|
|
건강 관련 삶의 질(HR-QoL) 점수
기간: 약 27-30주까지
|
약 27-30주까지
|
공동 작업자 및 조사자
수사관
- 연구 의자: Yongsheng Jia, Tianjin Medical University Cancer Institute and Hospital
- 수석 연구원: Jun Zhang, Tianjin Medical University Cancer Institute and Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .